KRAS and cancer: The number of codons that were identified as hotspots for mutation in the top 20 genes for each cancer type are shown in Figure 2B. The percentage of gene‐specific mutations that each mutant codon represents is depicted in Figure 2C. For example, KRAS codon 12 mutations are detected in 60% of pancreatic cancers (Fig. 2C and Table S4 “Percent of Total Cancers the Codon Represents”), whereas KRAS codon 12 mutations account for 92.74% of KRAS‐mutated pancreatic cancers (Fig. 2D and Table S4 “Percent of Gene‐specific Mutant Cancers each Codon Represents”).